阿柏西普8mg与法瑞西单抗治疗视网膜静脉阻塞性黄斑水肿:系统综述与网络荟萃分析
该研究通过系统综述与频率学派网络荟萃分析间接比较阿柏西普8mg与法瑞西单抗治疗视网膜静脉阻塞相关黄斑水肿的疗效与安全性,纳入3项试验共2174名成人。结果显示两者总体视力疗效相当,阿柏西普8mg可能提高达到驾驶视力阈值的概率,而法瑞西单抗可能提供更好的解剖学干燥和更低的急性眼压升高风险。
要点
- 阿柏西普8mg与法瑞西单抗平均BCVA改善无差异证据。
- 法瑞西单抗完全消除视网膜内/下积液率更高(RR 1.12)。
- 阿柏西普8mg注射后30-60分钟临床显著眼压升高风险更高。
核心结论
- 阿柏西普8mg与法瑞西单抗在视网膜静脉阻塞相关黄斑水肿的总体视力疗效上相当。
- 间接比较提示阿柏西普8mg可能增加达到驾驶视力的概率,法瑞西单抗可能提供更好的解剖学干燥和更低的急性眼压升高风险。
研究设计与样本
- 研究为系统综述与频率学派网络荟萃分析,检索MEDLINE、Embase和Cochrane CENTRAL自建库至2025年12月11日。
- 纳入3项试验共2174名成人,以每4周阿柏西普2mg为共同对照,评估负荷期完成时(24-40周)的疗效与安全性结局。
主要发现
- 每8周阿柏西普8mg(五次每4周负荷剂量)相比每4周法瑞西单抗更可能达到BCVA≥69字母(Snellen 20/40,无条件驾驶阈值),RR 1.18(95%CI 1.03-1.35)。
- 每4周法瑞西单抗相比每8周阿柏西普8mg(五次和三次每4周负荷剂量)完全消除视网膜内和视网膜下积液率更高,RR均为1.12(95%CI 1.01-1.25)。
- 两种药物平均BCVA改善无差异证据。
- 阿柏西普8mg和2mg方案相比每4周法瑞西单抗注射后30-60分钟临床显著眼压升高风险更高:每8周阿柏西普8mg(五次负荷)RR 6.42(95%CI 1.85-22.34),每8周阿柏西普8mg(三次负荷)RR 6.97(95%CI 2.02-24.08),每4周阿柏西普2mg RR 2.12(95%CI 1.01-4.47)。
临床怎么用
- 对于视网膜静脉阻塞相关黄斑水肿,阿柏西普8mg和法瑞西单抗总体视力疗效相当,选择时可综合考虑驾驶视力需求、解剖学干燥需求和急性眼压升高风险。
- 使用阿柏西普8mg或2mg方案时,需关注注射后30-60分钟的急性眼压升高风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema. METHODS: We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24-40 weeks), with 4 weekly aflibercept 2 mg as the common comparator. RESULTS: Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30-60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47). CONCLUSION: Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation. PROSPERO REGISTRATION NUMBER: CRD420251249785.
引用
- Liu Z, Surendran SA, Chong EW, et al. Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis. Br J Ophthalmol. 2026. PMID: 42629172. doi:10.1136/bjo-2026-330185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。